Cancer agents show first-line potential.
Hampton
Tracy
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D000068258:Bevacizumab; D000069439:Dasatinib; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007938:Leukemia / Q000188:drug therapy*; D010087:Oxides / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D011743:Pyrimidines; D013844:Thiazoles; D000068258:Bevacizumab; D000069439:Dasatinib; D000077237:Arsenic Trioxide